Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 14/20 | 1.00 |
| ▸ | AGXT | P21549 | 12/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7226604 | 0.98 | IDO1 (1.00) | IDO1AGXTTAAR1CYP3A4 | |
| SCHEMBL29193356 | 0.93 | IDO1 (0.86) | IDO1AGXTCYP3A4 | |
| SCHEMBL20469087 | 0.85 | IDO1 (1.00) | IDO1AGXTCYP3A4 | |
| SCHEMBL7948 | 0.85 | — | — | |
| SCHEMBL8863651 | 0.82 | IDO1 (0.94) | IDO1AGXTCYP3A4 | |
| SCHEMBL8021019 | 0.82 | IDO1 (0.94) | IDO1AGXTCYP3A4 | |
| Bromide SCHEMBL8996427 | 0.82 | IDO1 (0.94) | IDO1AGXTCYP3A4 | |
| Hydrochloric Acid SCHEMBL128937 | 0.82 | AGXT (1.00) | IDO1AGXTCYP3A4 | |
| Hydrochloric Acid SCHEMBL27822689 | 0.82 | AGXT (1.00) | IDO1AGXTCYP3A4 | |
| Hydrochloric Acid SCHEMBL26910207 | 0.82 | AGXT (1.00) | IDO1AGXTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
| JP-2007513098-A | — | — | 2007-05-24 | — | — | JP | claimed |
| EP-1697312-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| WO-2005054179-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2005-06-16 | — | — | WO | claimed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| CN-1906155-B | Novel hydroxamic acid ester derivant and pharmaceutical use thereof | LEO PHARMA AS | 2010-06-23 | — | — | CN | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| EP-1697312-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1266887-B1 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005054179-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2005-06-16 | — | — | WO | disclosed |
| EP-1266887-A2 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
| EP-0015456-B1 | OMEGA-HALOGENO-ACETOPHENONE OXIME ETHERS, PREPARATION THEREOF AND THEIR USE AS INTERMEDIATES IN THE PREPARATION OF OMEGA-AZOLYL-ACETOPHENONE OXIME ETHERS | BAYER AG (DE) | 1981-12-02 | — | — | EP | disclosed |
| US-4293715-A | FUNGICIDES, BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | IDO1 1074/4885AGXT 1676/4885TAAR1 4777/4885 |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | IDO1 3029/4885AGXT 131/4885TAAR1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.